Benzinga

Benzinga

Benzinga

miércoles, agosto 19

Fulcrum Therapeutics Inc

FULCNASDAQ
Trade with Public
Trade with Public
$3.87
0.030.78%
al cierre: Aug 17, 5:00 PM EST
$3.80
-0.0378-0.98%
Premercado: 4:56 AM EST
Fusiones y adquisiciones: Slate Medicines, Inc. announced it will be merged with Fulcrum Therapeutics (FULC) on Monday, August 17, 2026
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Fulcrum Therapeutics Financials

Fulcrum Therapeutics (FULC) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Earnings Scheduled For April 27, 2026

Benzinga Insights

PRO
Fulcrum Therapeutics Q1 EPS $(0.25) Beats $(0.30) Estimate, Ended The First Quarter Of 2026 With $333.3M In Cash, Cash Equivalents, And Marketable Securities; Cash Runway Into 2029

Benzinga Newsdesk

PRO
Fulcrum Therapeutics Q4 EPS $(0.31), Inline

Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.31) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
Benzinga Newsdesk

Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump

Avi Kapoor

Earnings Scheduled For October 29, 2025

Benzinga Insights

PRO
Fulcrum Therapeutics Q3 EPS $(0.31) Misses $(0.29) Estimate; Cash $200.6M

Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.29) by 6.9 percent. This is a 3.13 percent increase over losses of $(0.32) per share
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved